Respiratory Trials·org

Topic

Interstitial lung disease

Antifibrotics in IPF and progressive fibrosing ILD, and what immunosuppression does.

Antifibrotics slow the slope; they do not reverse fibrosis. Pirfenidone (ASCEND) and nintedanib (INPULSIS) were published together in 2014 and ended the era in which IPF had no treatment. Neither individually demonstrated a mortality benefit. That distinction is the substance of every honest conversation with a newly diagnosed patient.

The field then stopped enrolling by diagnosis and started enrolling by behaviour. INBUILD took fibrosis that was progressing, whatever its cause, and found nintedanib slowed decline anyway — creating progressive pulmonary fibrosis as a treatable entity. Nintedanib also works in scleroderma-associated ILD, though the result there is fragile under sensitivity analysis and nothing outside the lung improved (SENSCIS).

Newer agents add to what patients already take, which is the real advance. Nerandomilast slowed FVC decline in IPF with three quarters of participants on background antifibrotics (FIBRONEER-IPF) and in progressive pulmonary fibrosis (FIBRONEER-ILD). Inhaled treprostinil did the same in IPF without requiring pulmonary hypertension (TETON-2).

Immunosuppression has not disappeared. In inflammatory NSIP-pattern disease, adding rituximab to mycophenolate improved lung function and progression-free survival, at the cost of viral infection (EVER-ILD). In pulmonary sarcoidosis, methotrexate matched prednisone as first-line treatment, so the choice can now be made on side effects (PREDMETH).

Antifibrotics in IPF

Trial Year Therapy Effect Finding
TETON-2 2026 Inhaled treprostinil Inhaled treprostinil slowed FVC decline in IPF, in patients mostly already on antifibrotics
FIBRONEER-IPF 2025 Nerandomilast Nerandomilast slowed FVC decline on top of existing antifibrotics — the first genuinely additive agent in IPF
ASCEND 2014 Pirfenidone Pirfenidone slowed FVC decline and improved progression-free survival in IPF
INPULSIS 2014 Nintedanib Nintedanib roughly halved the annual rate of FVC decline in IPF, at the cost of diarrhoea

Antifibrotics beyond IPF

Trial Year Therapy Effect Finding
FIBRONEER-ILD 2025 Nerandomilast Nerandomilast slowed FVC decline in progressive pulmonary fibrosis, including on top of nintedanib
INBUILD 2019 Nintedanib Nintedanib slowed FVC decline across progressive fibrosing ILD, whatever the underlying diagnosis
SENSCIS 2019 Nintedanib Nintedanib slowed lung function decline in scleroderma ILD, but the result is fragile and skin disease was unchanged

Immunosuppression in connective tissue ILD

Trial Year Therapy Effect Finding
EVER-ILD 2023 Rituximab plus mycophenolate Adding rituximab to mycophenolate improved lung function in NSIP-pattern ILD, with more viral infection

Treating pulmonary sarcoidosis

Trial Year Therapy Effect Finding
PREDMETH 2025 Methotrexate Methotrexate matched prednisone as first-line treatment for pulmonary sarcoidosis, with a different side-effect profile

Key references

Guidelines, standards and reviews for this topic.

Studies not yet summarised

On the reading list for this topic and awaiting a full record. Listed here so nothing is hidden.